Jacobs Levy Equity Management
IOVA icon

Jacobs Levy Equity Management’s Iovance Biotherapeutics IOVA Stock Holding History

Jacobs Levy Equity Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,788
Closed -$34.9K – 1014
2025
Q4 		$34.9K Buy
+12,788
New +$29.6K ﹤0.01% 916
2025
Q2 		– Sell
-1,258,561
Closed -$4.19M – 1102
2025
Q1 		$4.19M Buy
+1,258,561
New +$6.49M 0.02% 502
2023
Q3 		– Sell
-515,035
Closed -$3.63M – 1010
2023
Q2 		$3.63M Sell
515,035
-1,045,893
-67% -$7.49M 0.02% 464
2023
Q1 		$9.54M Buy
1,560,928
+1,099,468
+238% +$7.59M 0.06% 293
2022
Q4 		$2.95M Buy
461,460
+276,063
+149% +$2.16M 0.02% 480
2022
Q3 		$1.78M Buy
185,397
+14,743
+9% +$170K 0.01% 583
2022
Q2 		$1.88M Buy
+170,654
New +$2.24M 0.01% 613

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Jacobs Levy Equity Management's IOVA Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 12,788 shares — an estimated $34.9K sold.

Jacobs Levy Equity Management first reported a position in IOVA in Q2 2022 and held it in 7 quarters. The position peaked at $9.54M in Q1 2023. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 12,788 Iovance Biotherapeutics shares in Q1 2026, an estimated $34.9K.
  • Jacobs Levy Equity Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Iovance Biotherapeutics position peaked at $9.54M in Q1 2023.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.